Bristol-myers Squibb Compnay

Stephan Roy

Anne Marinier

Mark D Wittman

Kurt Zimmermann

Neelakantan Balasubramanian

Xiaopeng Sang

David R Langley

Mark George Saulnier

Alain Martel

Upender Velaparthi

David Bertil Frennesson

Peiying Liu

Francis Beaulieu

Carl Ouellet

James G Tarrant

Marco Dodier

Karen M Stoffan

Makonen Belema

Van N Nguyen

Jacques Banville

Yuping Qiu

Ramkumar Rajamani

Patrice Gill

Yunhui Zhang

Claude A Quesnelle

Amy Mae Bunker

Serge Plamondon

Yonghua Gai

Xuejie Yang

Christopher Zusi

Claude Quesnelle

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.

Thiazolyl compounds useful as kinase inhibitors

The invention provides compounds of formula II: and pharmaceutically acceptable salts thereof. The formula II thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

The present invention provides compounds having formula I and their use for the treatment of cancer.

Imidazole based kinase inhibitors

Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Benzimidazole C-2 heterocycles as kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

Tyrosine kinase inhibitors

Compounds having the formula (I),and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R, R, and Rare hydrogen, halogen, alkyl, or perfluoroalkyl; Ris an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and Ris a substituent on A as defined in the specification.

Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same

Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors

Growing community of inventors

St-Lambert, Canada

Stephan Roy